Home > Riviste > Minerva Endocrinology > Fascicoli precedenti > Articles online first > Minerva Endocrinology 2021 May 14

ULTIMO FASCICOLO
 

JOURNAL TOOLS

eTOC
Per abbonarsi
Sottometti un articolo
Segnala alla tua biblioteca
 

ARTICLE TOOLS

Publication history
Estratti
Permessi
Per citare questo articolo
Share

 

 

Minerva Endocrinology 2021 May 14

DOI: 10.23736/S2724-6507.21.03363-7

Copyright © 2021 EDIZIONI MINERVA MEDICA

lingua: Inglese

Evaluation of thyroid disease and thyroid malignancy in acromegalic patients

Yılmaz CANKURTARAN 1 , Güzide G. ÖRÜK 2, Büşra TOZDUMAN 3

1 Department of Internal Medicine, İzmir Kâtip Çelebi University, Atatürk Training and Research Hospital, İzmir, Turkey; 2 Division of Endocrinology and Metabolism, Department of Internal Medicine, İzmir Kâtip Çelebi University, Atatürk Training and Research Hospital, İzmir, Turkey; 3 Department of Public Health, İzmir Kâtip Çelebi University, Atatürk Training and Research Hospital, İzmir, Turkey


PDF


BACKGROUND: Differences in epidemiological data from different geographical regions have made the prevalence of thyroid disease and thyroid cancer controversial. No previous study has investigated whether thyroid disease and thyroid cancer prevalence are higher in acromegalic patients than in the general population in Turkey. The aim of this study is to determine the prevalence of thyroid disease and thyroid cancer in acromegaly and to compare it with the control group.
METHODS: A total of 129 acromegalic patients (78 female, 51 male) and 247 control group patients (151 female, 96 male) were included in the study. Pituitary size, growth hormone (GH) and insulin-like growth factor (IGF)-1 levels in all patients with acromegaly and thyroid function tests, thyroid receptor autoantibody (TRAb), thyroid scintigraphy, thyroid ultrasonography (US), fine needle aspiration cytology (FNAC) and histopathology findings after thyroidectomy were recorded.
RESULTS: Thyroid lesions were present in 93 patients (72.1%) with acromegaly. While diffuse goiter (14.7%) and multinodular goiter (MNG) (47.3%) were significantly higher, Graves’ disease (4.5%) was significantly lower in the acromegaly group compared to control group. The presence of thyroid lesions and thyroid nodules was significantly higher in patients with acromegaly (Odds ratio (OR) 2.766; 95% CI 2.112-4.469, p <0.001 and OR 1.955; 95% CI 1.206-3.170, p = 0.007). According to gender, the prevalence of thyroid lesions, MNG and thyroid cancer was significantly higher in female patients than in the control group. Thyroid cancer prevalence was found in 7% of acromegalic patients and the prevalence of thyroid cancer in the control group was 4.5%.
CONCLUSIONS: It remains controversial whether the risk of thyroid cancer is increased or not in patients with acromegaly. In this study, there is no significant difference in thyroid cancer between acromegaly and control group, but thyroid lesions are significantly more common in acromegaly. Also, more research is required to determine if thyroid lesions are more prevalent in females with acromegaly.


KEY WORDS: Acromegaly; Thyroid cancer; Thyroid lesions; Thyroid nodules

inizio pagina